|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N02AX06
|
|
gptkbp:bioavailability
|
32%
|
|
gptkbp:brand
|
gptkb:Nucynta
gptkb:Palexia
|
|
gptkbp:broadcastOn
|
gptkb:Schedule_II_(US)
|
|
gptkbp:CASNumber
|
175591-23-8
|
|
gptkbp:contraindication
|
paralytic ileus
acute or severe bronchial asthma
severe respiratory depression
|
|
gptkbp:developedBy
|
gptkb:Grünenthal_GmbH
|
|
gptkbp:discoveredBy
|
gptkb:Grünenthal_GmbH
|
|
gptkbp:drugClass
|
analgesic
opioid
|
|
gptkbp:eliminationHalfLife
|
4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
2003
|
|
gptkbp:form
|
extended-release tablet
immediate-release tablet
|
|
gptkbp:hasMolecularFormula
|
C14H23NO
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tapentadol
|
|
gptkbp:IUPACName
|
3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
20%
|
|
gptkbp:PubChem_CID
|
8014292
9838022
|
|
gptkbp:riskFactor
|
respiratory depression
dependence
abuse potential
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
dizziness
somnolence
|
|
gptkbp:synonym
|
(1R,2R)-3-(dimethylamino)-1-ethyl-2-methyl-3-phenylpropan-1-ol
|
|
gptkbp:UNII
|
H8A007M585
|
|
gptkbp:usedFor
|
pain management
moderate to severe pain
|
|
gptkbp:bfsParent
|
gptkb:Schedule_II
|
|
gptkbp:bfsLayer
|
6
|